⚡ Postpartum Seizure (non-eclamptic differentials)
IN REVIEWPENDING CLINICAL VERIFICATIONTIME-CRITICAL PROTOCOL
1 RECOGNIZE
- Any new postpartum seizure is an emergency. Eclampsia can occur later than 48 h and without previously documented hypertension; do not exclude it using that timing alone.
- Consider hypoglycaemia, eclampsia/PRES, cerebral venous thrombosis, haemorrhage/stroke, infection, epilepsy, electrolyte disturbance and drug toxicity.
2 CALL FOR HELP
- Call anaesthesia/resuscitation, senior obstetrician and neurology/critical care; start seizure timing and record recovery between events.
3 IMMEDIATE ACTION
- Protect the airway, position laterally, prevent injury, give oxygen for hypoxaemia and obtain IV access. Check bedside glucose immediately and treat hypoglycaemia.
- Treat suspected eclampsia with ONE magnesium regimen even if BP is not currently high, while evaluating alternative causes. Treat severe BP separately when present.
- Convulsions lasting ≥5 min or recurrent without recovery need the convulsive-status pathway with airway support. Use the stated benzodiazepine regimen, counting prior doses; persistent status needs a second-line loading agent and ICU.
- Labetalol is an antihypertensive, NOT an alternative anticonvulsant. Do not substitute BP treatment for seizure treatment.
Drug doses & preparation
Choose the regimen for the stated indication. Alternatives are not instructions to give every medicine. Check prior doses, contraindications, concentration and the response before repeating.
Glucose — severe hypoglycaemiaJBDS-IP / ABCD / Diabetes UKchecked
Dose20 g glucose: 200 mL of 10% OR 100 mL of 20% solution
RouteIV infusion
FrequencyGive over 10–15 min; recheck glucose at 10 min and repeat if still <4 mmol/L with reassessment
DurationAcute rescue followed by longer-acting carbohydrate when awake and safe to swallow, or prescribed ongoing infusion
Preparation10% =100 mg/mL; 200 mL =20 g. 20% =200 mg/mL; 100 mL =20 g. Check IV patency and use a limited volume so a whole large bag cannot infuse accidentally
Max doseReassess after each 20 g treatment; recurrent/prolonged hypoglycaemia needs monitored ongoing treatment
- Indication: Impaired consciousness or unsafe swallowing; never give oral fluid to an unconscious patient
Monitoring
- Glucose 10 min after treatment, then serially until stable; consciousness, swallow and IV site
- Identify missed food, insulin excess, renal failure or infection; do not omit basal insulin in type 1 diabetes
Contraindications: Do not give oral sugar when swallowing is unsafe; hypertonic glucose extravasation can injure tissue
Magnesium sulfate — IV/IM regimenMSFchecked
Dose4 g IV loading, then 5 g deep IM into EACH buttock (10 g IM total); maintenance 5 g IM into alternate buttocks
RouteIV loading + deep IM
FrequencyLoading once; maintenance every 4 hours
DurationContinue until 24 hours after birth OR the last seizure, whichever is later
PreparationUsing 50% (500 mg/mL): 4 g = 8 mL; dilute in 100 mL sodium chloride 0.9% and infuse over 15–20 min. Each 5 g IM dose = 10 mL of 50% solution. Check the actual ampoule strength.
Max doseDo not give maintenance when toxicity criteria are present; do not run an additional magnesium regimen
- Indication: Eclampsia: stop seizures and prevent recurrence
Monitoring
- Check patellar reflexes, respiratory rate and hourly urine output; monitor BP, pulse and consciousness
- Withhold magnesium for absent reflexes, respiratory rate <12/min or urine <100 mL in 4 h; obtain serum magnesium and senior review
- Stop magnesium and support ventilation for toxicity; give the calcium-gluconate antidote shown below
Contraindications: Myasthenia gravis, heart block or magnesium toxicity · Renal impairment or oliguria requires reduced/withheld maintenance and more frequent assessment
Magnesium sulfate — IV regimenMSFchecked
Dose4 g IV loading over 15–20 min, then 1 g/hour
RouteIV infusion
FrequencyOne loading dose, then continuous infusion
Duration24 hours after birth or last seizure, whichever is later
Preparation50% solution: withdraw 8 mL (4 g) into 100 mL sodium chloride 0.9% for loading; for maintenance make 20 g up to a FINAL 100 mL (200 mg/mL), run at 5 mL/hour by labelled pump
Max doseUse ONE IV or IV/IM protocol; stop/adjust for toxicity or renal dysfunction
- Indication: Eclampsia: alternative when a reliable infusion pump and monitoring are available
- Maintenance concentration and pump rate are calculated from the prescribed 1 g/hour; independently check the preparation.
Monitoring
- Check patellar reflexes, respiratory rate and hourly urine output; monitor BP, pulse and consciousness
- Withhold magnesium for absent reflexes, respiratory rate <12/min or urine <100 mL in 4 h; obtain serum magnesium and senior review
- Stop magnesium and support ventilation for toxicity; give the calcium-gluconate antidote shown below
Contraindications: Myasthenia gravis, heart block or magnesium toxicity · Renal impairment or oliguria requires reduced/withheld maintenance and more frequent assessment
Magnesium sulfate — recurrent seizureMSFchecked
Dose2 g IV additional dose after senior assessment
RouteIV infusion
FrequencyOne rescue dose, followed by reassessment
DurationAcute rescue; continue the selected maintenance regimen
Preparation50% solution: 2 g = 4 mL, dilute in compatible sodium chloride 0.9%; give slowly by infusion and check the total loading already received
Max doseMSF ceiling: no more than 8 g IV in the first hour; persistent fits need anaesthesia/ICU, not repeated blind magnesium dosing
- Indication: Recurrent eclamptic convulsion after loading; reassess airway, glucose and magnesium toxicity
Monitoring
- Check patellar reflexes, respiratory rate and hourly urine output; monitor BP, pulse and consciousness
- Withhold magnesium for absent reflexes, respiratory rate <12/min or urine <100 mL in 4 h; obtain serum magnesium and senior review
- Stop magnesium and support ventilation for toxicity; give the calcium-gluconate antidote shown below
Contraindications: Myasthenia gravis, heart block or magnesium toxicity · Renal impairment or oliguria requires reduced/withheld maintenance and more frequent assessment
Calcium gluconate 10%MSFchecked
Dose1 g (10 mL of 10% solution) slowly
RouteIV
FrequencyInitial antidote dose; reassess breathing, ECG and calcium before further dosing
DurationEmergency reversal; stop magnesium and support the airway concurrently
Preparation10% = 100 mg/mL; 10 mL contains 1 g calcium gluconate, NOT 1 g elemental calcium. Give over at least 5 min through a patent IV line; do not mix with other drugs
Max doseNo automatic repeated-dose course; further calcium requires monitored reassessment
- Indication: Antidote for clinically significant magnesium toxicity
Monitoring
- Continuous ECG/heart rate; respiratory status, reflexes and injection site; serum calcium/magnesium where available
Contraindications: Extravasation can cause tissue injury; take special care with digoxin · Do not confuse calcium gluconate with calcium chloride
Lorazepam — convulsive statusNHS Greater Glasgow and Clydechecked
Dose2 mg IV over 1 min; if not terminating, another 2 mg after 2–3 min (up to 4 mg); a repeat benzodiazepine dose at 10 min if still seizing under the GGC pathway
RouteSlow IV
FrequencyInitial staged dose; at most one repeat treatment before moving to second-line therapy
DurationTime-critical rescue; prepare airway/ventilation and second-line therapy concurrently
PreparationUse the actual IV lorazepam product; dilute according to its label. Prescribe in mg and verify mg/mL, including any dilution
Max dose4 mg initial treatment; count any benzodiazepine already given. Persistent status needs second-line loading and ICU, not endless benzodiazepines
- Indication: Seizure lasting ≥5 min or recurrent seizures without recovery; also assess/treat eclampsia when possible
Monitoring
- Airway, respiratory rate, SpO2, BP, ECG and glucose; assisted ventilation capability immediately available
Contraindications: Respiratory depression is a major risk, especially after prior sedatives; do not mix several benzodiazepine schedules
Levetiracetam — status loadingNHS Greater Glasgow and Clydechecked
Dose60 mg/kg, maximum 4500 mg
RouteIV infusion
FrequencyOne loading dose with urgent reassessment
DurationEmergency loading; ongoing maintenance is a separate neurology prescription
Preparation100 mg/mL concentrate: prescribed mg ÷100 =mL to withdraw. Dilute the dose in at least 100 mL compatible sodium chloride 0.9% and infuse over 15 min (Keppra product preparation); the 60 mg/kg, maximum 4500 mg status load is off-label GGC emergency guidance.
Max dose4500 mg per loading dose
- Indication: Ongoing convulsive status after adequate first-line benzodiazepine treatment; non-eclamptic cause or seizures refractory to eclampsia care
Monitoring
- Respiratory/circulatory monitoring, clinical seizure termination and EEG if consciousness fails to recover; renal function for subsequent maintenance
Contraindications: Known levetiracetam allergy; persistent status needs anaesthesia/ICU and evaluation of cause
4 INVESTIGATIONS (never delaying treatment)
- Glucose, CBC/platelets, electrolytes including sodium/calcium/magnesium, renal/LFTs, coagulation and blood gas; infection/toxicology/antiepileptic levels if appropriate.
- Urgent neuroimaging for focal signs, prolonged altered consciousness, atypical/refractory seizures or suspected intracranial disease; CT/MRI and venous imaging are chosen for the suspected diagnosis.
5 DEFINITIVE MANAGEMENT
- Manage persistent convulsions as status: second-line loading, anaesthesia/ventilation when needed and EEG for possible non-convulsive status after motor activity stops.
- Confirmed cerebral venous thrombosis, stroke/haemorrhage, CNS infection or epilepsy requires its specific neurology-led treatment; do not start blanket anticoagulation before defining the diagnosis and bleeding risk.
- Review magnesium/benzodiazepine exposure, renal function and interacting medicines; use calcium and ventilation for magnesium toxicity.
6 ESCALATION
- Airway compromise, persistent seizures, coma, focal deficit or deteriorating physiology: ICU/neurology immediately.
7 POST-EVENT CARE
- Monitor consciousness, neurological examination, BP, respiration and recurrence; continue cause-specific treatment and arrange neurological/obstetric follow-up.
- Discuss medication implications, driving/local safety restrictions, breastfeeding and recurrence planning once stable.
Admission & discharge after the acute event
Care setting: Hospital assessment; severe disease needs admission and possible critical care
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Admit for severe/persistent hypertension, seizure or neurological symptoms, pulmonary oedema, renal/liver/platelet deterioration, significant pain or fetal compromise.
- Eclampsia/HELLP or organ-support needs require appropriate high-dependency/critical-care monitoring, with transfer after initial stabilisation when necessary.
When clinic, day care or home care may be suitable
- Outpatient follow-up is suitable only after postnatal symptoms, BP, blood results and access to surveillance meet the individual plan. Recent seizure or HELLP requires hospital recovery first.
Before going home
- Postnatal NICE transfer criteria: no pre-eclampsia symptoms, BP ≤150/100 mmHg with or without treatment, and blood results stable or improving; all criteria must be met.
- Following eclampsia/HELLP, complete indicated seizure prophylaxis/monitoring and document neurological, respiratory, urine-output and blood-test recovery before considering home care. Critical-care step-down and discharge home are separate decisions.
Discharge medicines and treatment changes
- Continue the selected oral antihypertensive. Stop methyldopa within 2 days after birth; document replacement and review.
- The prescriber should consider reduction below 140/90 and reduce below 130/80 mmHg under NICE; provide an individual written adjustment plan. Magnesium loading/infusions are inpatient treatment, not take-home medication.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
One selected oral BP option; do not prescribe every alternative together.
Labetalol oralMSFchecked
DoseStart 100 mg twice daily; increase by 100–200 mg increments according to BP; higher daily doses divided three times daily
RouteOral
FrequencyTwice daily initially; three divided doses if higher doses needed
DurationContinue while clinically required; titrate down rather than stop abruptly, with a postpartum review plan
Preparation100 mg or 200 mg tablets; prescribe the strength, dose and administration times
Max dose2400 mg/day
- Indication: Maintenance hypertension during pregnancy/postpartum
Monitoring
- BP/heart rate, postural symptoms; neonatal glucose/heart-rate observation after late-pregnancy exposure
Contraindications: Asthma, heart block, marked bradycardia, decompensated heart failure
Alternative/adjunct only within the documented BP plan.
Nifedipine extended releaseGovernment of India, MoHFW / NHMchecked
DoseStart sustained-release nifedipine 10 mg twice daily; titrate according to BP and the exact release formulation
RouteOral extended release
FrequencyTwice daily for the cited sustained-release regimen
DurationWhile hypertension persists; reassess after birth and reduce when BP allows
PreparationUse the specified sustained-release tablet, swallowed intact. Other extended-release products may use different strengths/schedules; do not interchange them or use them for acute oral loading.
Max dose80 mg/day for the NHM CEmONC sustained-release regimen
- Indication: Maintenance hypertension in pregnancy/postpartum
Monitoring
- BP, headache, flushing, oedema and pulse
Contraindications: Maternal hypotension or significant cardiac outflow obstruction
Postpartum only when prescribed, with renal function/potassium monitoring.
Enalapril — postpartum hypertensionMilpharm / emcchecked
DoseStart 5 mg once daily; use a lower supervised initial dose if volume depleted or renally impaired; titrate to BP response
RouteOral
FrequencyOnce daily initially
DurationReview BP and dose after birth; reduce/stop as hypertension resolves or continue for persistent hypertension after medical review
Preparation5 mg tablet swallowed with water, with or without food. Correct volume depletion; check creatinine and potassium before starting
Max dose40 mg/day in the product label; usual maintenance 20 mg/day, not an automatic postpartum target
- Indication: After birth only; NICE recommends enalapril with maternal renal-function and potassium monitoring
- Renal / hepatic: Renal impairment requires a lower initial dose and adjustment from the product renal table, not the unadjusted 5 mg starter.
- NICE NG133 supplies the postpartum choice. Breastfeeding requires extra caution with premature/very young infants; use a suitable alternative when clinically indicated.
Monitoring
- BP, symptoms, creatinine/eGFR and potassium before and after initiation/dose changes; infant feeding, alertness and urine output if breastfeeding
Contraindications: Pregnancy, prior ACE-inhibitor angioedema, significant hyperkalaemia; avoid starting in unresolved AKI or severe volume depletion
Tests, pending results and their reviewer
- Review platelet count, transaminases and creatinine at 48–72 hours after birth/critical-care step-down; abnormal results need a repeat plan until recovery.
- At 6–8 weeks check urine protein; persistent proteinuria (1+ or more) needs a 3-month renal review and referral if kidney function is abnormal.
Home care and counselling
- Provide the BP schedule, named reviewer, medicine list and explicit severe-symptom instructions. Discuss recurrence, future-pregnancy planning and long-term cardiovascular risk.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
If on antihypertensives: every 1–2 days for up to 2 weeks after transfer | NICE BP surveillance until off treatment with no hypertension; adapt intensity to findings. |
If not on antihypertensives: day 3–5 after birth | Check BP; repeat on alternate days if abnormal. |
2 weeks if still on treatment; 6–8 weeks for all | Review medicines, BP, recovery and urine protein; arrange renal follow-up when indicated. |
Return urgently
- Seizure, severe/persistent headache, visual disturbance, epigastric pain, dyspnoea, chest pain or severe BP: return immediately; postpartum onset can occur after discharge.
Sources
MSFcheckedNHS Greater Glasgow and ClydecheckedNICEcheckedJBDS-IP / ABCD / Diabetes UKcheckedMSFcheckedNICE · NG133checkedMSFcheckedGovernment of India, MoHFW / NHMcheckedMilpharm / emccheckedNICE · NG194, recommendationscheckedIndia MoHFW / NHM · LaQshya district-hospital SOP, linked editioncheckedWHO · 2022 official recommendation summarycheckedRCOG · Current public recovery informationcheckedNICE · CG50, recommendationschecked